Reliability and validity of the brief Dimensional Apathy Scale (b-DAS) by Radakovic, Ratko et al.
Reliability and validity of the brief Dimensional 
Apathy Scale (b-DAS) 
 
 
Ratko Radakovic 1234*, Debbie Gray 256, Kaitlin Dudley 13, Eneida Mioshi 1, David Dick 3, 
Giulia Melchiorre 56, Harry Gordon 56, Judith Newton 56, Shuna Colville 56, Suvankar Pal 
56, Siddharthan Chandran 56, Sharon Abrahams 256 
 
1. Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, United Kingdom, 
NR4 7TJ. 
2. Euan MacDonald Centre for Motor Neurone Disease Research, Royal Infirmary of Edinburgh, 
Edinburgh, United Kingdom, EH16 4SB. 
3. Norfolk and Norwich University Hospital, Norwich, United Kingdom, NR4 7UY. 
4. Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, United 
Kingdom, EH8 9JZ. 
5. Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, United 
Kingdom, EH16 4SB. 
6. Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom, EH8 9JZ. 
 
 
Word count: 1515 
 
                                                        
* Corresponding author. Email address: r.radakovic@uea.ac.uk; radakovic.ratko@gmail.com  




Objective: Apathy is composed of different demotivational subtypes measurable by the 
Dimensional Apathy Scale (DAS) and can be quickly assessed using the brief DAS (b-
DAS). The aim was to determine the reliability and validity of the b-DAS. Method: 53 
Amyotrophic Lateral Sclerosis (ALS) patients and 53 of their informants were recruited. 
Informants completed the b-DAS, the original informant/carer-rated DAS and 
behavioural interview about the patients (i.e. presence of behaviours such as 
Apathy/Inertia, Loss of sympathy/empathy). Patients completed measures of 
depression, anxiety, emotional lability, cognitive functioning and functional disability 
measures. Results: The b-DAS showed good internal consistency, excellent test-retest 
reliability, significant positive correlation with the original DAS and no significant 
correlations with depression, anxiety, emotional lability, cognitive functioning or 
functional disability measures. Semi-structured behaviour interview showed patients 
with Apathy/Inertia had significantly higher b-DAS subscale scores and patients with 
Loss of sympathy/empathy had significantly higher Emotional apathy scores only. 
Conclusions: The b-DAS is a fast, reliable and valid instrument for screening apathy 










Apathy is the most common behavioural change reported in amyotrophic lateral 
sclerosis (ALS; Strong et al., 2017), and has been shown to have negative practical 
impact, such as caregiver burden (Burke, Elamin, Galvin, Hardiman & Pender, 2015), 
Apathy is a syndrome composed of different subtypes of demotivation (Radakovic & 
Abrahams, 2018). The Dimensional Apathy Scale (DAS; Radakovic & Abrahams, 2014) is 
a 24 item measure that can be used to assess Executive apathy (lack of motivation for 
organisation, planning or attention), Emotional apathy (lack of emotional motivation, 
indifference or emotional neutrality) and Initiation apathy (lack of motivation for self-
generation of thought and or/actions,) independent of motor disability (Radakovic et 
al., 2016). It has been validated in various neurological and neurodegenerative diseases, 
such as Parkinson’s disease (PD) and dementia (Radakovic, Davenport, Starr & 
Abrahams, 2018; Radakovic, Starr & Abrahams, 2017a), including ALS (Radakovic et al., 
2016), showing differential apathy profiles dependent on neurodegenerative disease. In 
ALS, Initiation apathy has been found to be characteristic (Radakovic et al., 2016; 
Santangelo et al., 2019) with distinct overlap with certain types of cognitive 
dysfunction, specifically the verbal fluency deficit (Radakovic et al., 2017b). Executive 
and Initiation apathy has been observed in PD, with impact on activities of daily living 
(Radakovic, et al., 2018) and global apathy over all subtypes supplemented by lower 
awareness has been observed in dementia, specifically Alzheimer’s disease (Radakovic 
et al., 2017a). 
 
The brief DAS (b-DAS) has recently been developed using item response analysis, a data 
driven scaling method, wherein the most robust items were selected from the original 
24 item informant/carer-rated DAS (Radakovic et al., In Press). This produced the b-
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DAS to be completed by informants/caregivers about patients, as a quick and 
comprehensive informant/carer-rated 9-item scale (with a supplementary awareness 
deficit/impairment assessment), with apathy subtype specific cutoffs. Given that it is 
becoming increasingly important to screen for apathy subtypes to determine their 
impact (Lanctôt et al., 2017) and there is an increasing focus on tailored practical 
management and non-pharmacological interventions relating to specific apathy profiles 
(Manera et al., In Press), the b-DAS was developed to be used within a busy clinical 
setting. 
 
In addition to apathy, cognitive impairment and other behavioural changes are common 
features in ALS and ALS-Frontotemporal spectrum disorder (Strong et al., 2017) and 
there are also other non-motor symptoms which can occur, such as depression, anxiety 
and emotional lability (Fang, Jozsa & Al-Chalabi, 2017). As such, due to the various non-
motor symptoms that can occur within ALS, it is important to determine convergent and 
divergent validity of the b-DAS against other apathy, depression, anxiety and emotional 
lability measures, while also exploring how this relates to functional disability, cognitive 
functioning and behaviour change. Therefore, the aim was to determine the reliability 
and validity of the b-DAS against standardised assessments of other symptoms and a 
semi-structured interview assessing abnormal behaviours. 
 
Methods 
Participants and Procedure 
53 ALS patients and 53 of their informants (caregivers/partners/relatives) were 
recruited for this research study. Participants were recruited from the United Kingdom. 
All patients were diagnosed using the El Escorial Revised Criteria (Brooks, Miller, Swash 
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& Munsat, 2000). Ineligibility criteria for the study included severe disability relating to 
disease progression that would hinder participation, severe diabetes, epilepsy, 
alcohol/substance- related disorders, or other traumatic or non-traumatic neurological 
insults (e.g. head injury requiring intensive care hospitalisation, and stroke). All 53 
patient-informants dyads undertook the interview below at their homes. Due to patient 
attrition (for reasons such as death or loss of contact), 43 (of the 53) ALS patient’s 
informants had the b-DAS re-administered approximately 3 months later to determine 
test-retest reliability. 
 
Ethical approval was obtained from National Health Service (NHS) Research Ethics 





Apathy was assessed using the informant/carer-rated b-DAS (Radakovic et al., In Press), 
a 9 item measure with each item scored on a 4 point Likert (ranging from 0 to 3). It is 
composed of 3 subscales assessing Executive, Emotional, and Initiation apathy, with the 
scores ranging from 0 (least apathetic) and the maximum score as 9 (most apathetic) 
for each subscale. Awareness of apathy subtype is also assessed for each item scored in 
the upper two points of the Likert Scale with Yes/No question (“Are they aware of this 
specific difficulty?”). Summed awareness scores (i.e. “No” answers) for each apathy 
subtype can range from 0 (No Awareness deficit/impairment) to 3 (Severe Awareness 
deficit/impairment). Validity was assessed against full informant/carer-rated DAS 
(Radakovic et al., 2016), a 24 item measure with each item scored on a 4 point Likert 
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composed of the 3 subscales with each score ranging from 0 (least apathetic) to 24 
(most apathetic). Due to the overlap of the b-DAS and informant/carer-rated DAS, 
informants completed the 9 item b-DAS and the remaining 15 items of the 24 item DAS. 
 
Depression was assessed using the 9-item Patient Health Questionnaire (PHQ-9; Löwe, 
Unützer, Callahan, Perkins & Kroenke, 2004): with each item is scored on a 4 point 
Likert Scale (ranging from 0 to 3), with the score ranging from 0 (least depressed) to 27 
(most depressed).  
 
Anxiety was assessed using the 7-item Generalised Anxiety Disorder questionnaire 
(GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006): with each item scored on a 4 point 
Likert Scale (ranging from 0 to 3), with the score ranging from 0 (least anxious) to 21 
(most anxious).  
 
Emotional lability was assessed using the 33-item Emotional Lability Questionnaire 
(ELQ; Newsom-Davis, Abrahams, Goldstein & Leigh, 1999): with three subsections for 
laughing, smiling and crying. Each subsection has 10 questions scored on a 4 point 
Likert scale (ranging from 0 to 3) and 1 question scored dichotomously (Yes = 1 and No 
= 0). The score ranges from 0 (not emotionally labile) to 93 (highly emotionally labile).  
 
Functional disability was assessed using 12-item ALS Functional Rating Scale-Revised 
(ALSFRS-R; Cedarbaum et al., 1999): with each item scored on a 5 point Likert scale 
(ranging from 0 to 4), with the score ranging from 0 (maximum disability) to 48 
(normal motor function). 
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Cognitive functioning was assessed using the Edinburgh Cognitive and behavioural ALS 
Screen (ECAS; Abrahams, Newton, Niven, Foley & Bak, 2014): is a brief 20-minute 
cognitive screen that assesses ALS specific cognitive domains (language, verbal fluency 
and executive functioning) and ALS non-specific cognitive domains (memory and 
visuospatial) with the total score ranging from 0 to 136: lower scores on the cognitive 
screen indicate cognitive impairment. Behaviour change was assessed using the ECAS 
behaviour interview (Abrahams et al., 2014), which is a semi-structured interview with 
the informants about the patient to determine changes or impairment in behavioural 
domains (behavioural disinhibition, apathy/inertia, loss of sympathy/empathy, 
perseverative, stereotyped or compulsive behaviour, hyperorality/altered food 
preference and psychosis) with a minimum score of 0 (no behaviour change) and 
maximum of 5 (most behaviour change). 
 
The b-DAS, informant/carer-rated DAS and ECAS behaviour interview were completed 
by/administered to the informants about their observations of the patients. The 
depression, anxiety, emotional lability and functional disability measures were 
completed by the patients. The ECAS Cognitive screen was administered to the patient 
by the researcher. 
 
Statistical analysis 
R and SPSS were used for analysis. Distribution of data was assessed using Shapiro-Wilk 
test, which determined the use of non-parametric. Cronbach’s Standardised alpha was 
used to examine internal consistency reliability. Intra-class correlation (ICC) was used 
to determine test-retest reliability. Correlational (Spearman’s Rho) analysis was used to 
examine psychometric concurrent and discriminant validity against other measures. 
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Comparative analysis (Kruskal Wallis Test and/or Mann-Whitney U test) with multiple 
comparisons correction (Holm method) was further utilised to examine convergent 




Table 1 shows demographic and clinical characteristics of the patients. 
 
Table 1. Clinical and Demographic variables of patients 
 ALS Patients (N=53) 
Male/Female 44/9 
Age (mean, SD) 68.0 (7.5) 
Years of Education (mean, SD) 11.3 (1.2) 
Disease duration, (median, IQR) months 11 (10) 
Site onset % (UL / LL / B / R / M / U) 34.0 / 26.4 / 20.8 / 5.7 / 5.7 / 7.5 
ALSFRS-R score (mean, SD) 34.7 (7.7) 
ECAS Cognitive score (mean, SD) 107.0 (14.1) 
ECAS Behaviour Domain score (median, IQR) 1 (2) 
PHQ-9 score (mean, SD) 5.9 (4.6) 
GAD-7 score (mean, SD) 3.1 (3.7) 
ELQ score (mean, SD) 6.7 (10.7) 
Informant/carer-rated DAS Executive (mean, SD) 6.1 (4.8) 
Informant/carer-rated DAS Emotional (mean, SD) 8.9 (4.2) 
Informant/carer-rated DAS Initiation (mean, SD) 12.1 (5.5) 
b-DAS Executive (mean, SD) 2.0 (2.0) 
b-DAS Emotional (mean, SD) 2.9 (1.9) 
b-DAS Initiation (mean, SD) 4.3 (2.6) 
SD = Standard Deviation; IQR = Interquartile Range; UL = Upper limb; LL = Lower limb; B = Bulbar; R = 
Respiratory; M = Mixed; U = Unknown; ALSFRS-R = ALS Functional Rating Scale-Revised; ECAS = 
Edinburgh Cognitive and behavioural ALS Screen; PHQ-9 = Patient Health Questionnaire-9; GAD-7 = 
Generalised Anxiety Disorder questionnaire; ELQ = Emotional Lability Questionnaire; DAS = Dimensional 
Apathy Scale; b-DAS = Brief DAS 
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The informants of the patients had a mean age of 62.6 (Standard Deviation = 11.6), 85% 
were female. The informants were most commonly a spouse/partner (86.8%), followed 
by daughter/son (5.7%), close friend (3.8%), sibling (1.8%) and parent (1.8%). There 
were no significant correlations between the b-DAS subscales and age, education or 
disease duration. Based on b-DAS cutoffs (Radakovic et al., In Press), 34.0% were 
impaired on Initiation apathy, compared to 17.3% on Emotional apathy and 24.5% on 
Executive apathy. Additionally, the test-retest participant group (N = 43) did not 
significantly differ on age and gender distribution from the original participant group (N 




The Cronbach’s Standardised alpha of the b-DAS was found to be 0.81, which was 
interpreted as good internal consistency reliability. The median interval for test-retest 
was 100 days (Interquartile Range = 9 days). Test-retest reliability for the b-DAS was 
excellent (ICC = 0.84). 
 
When examining convergent validity, the b-DAS and the original informant/carer-rated 
DAS subscales were observed to be significantly positively correlated (Executive rs(51) 
= .87, p < .001; Emotional rs(51) = .80, p < .001; Initiation rs(51) = .90, p < .001). See 
Supplementary Table 1 for details.  
 
Figure 1a shows patients that displayed Apathy/Inertia according to the ECAS 
behaviour interview had higher scores all b-DAS subscales compared to those that did 
not display apathy (Executive U = 173.5, p < .01; Emotional U = 153.3, p < .01; Initiation 
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U = 143.5, p < .01). Additionally, Figure 1b shows patients that displayed Loss of 
Sympathy/Empathy were found to have higher scores on only the b-DAS Emotional 
subscale compared to those that did not display Loss of Sympathy/Empathy (U = 124.5, 








In examining discriminant validity, the b-DAS subscales found not to be significantly 
correlated with the PHQ-9, the GAD-7 or the ELQ. Further, there was no significant 
correlation between the b-DAS and the ALSFRS-R or the ECAS Cognitive Total Score. See 
Supplementary Table 2 for details. 
 
Figure 1. b-DAS subscale scores for patients with (Yes) and without (No) a) Apathy/Inertia b) Loss of 
Sympathy/Empathy on the ECAS behaviour interview. 
Whiskers indicate range.        * p < .05; ** p < .01 
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On the b-DAS, 37.7% of patients had awareness impairment on one or more subscales. 
The total b-DAS awareness impairment score was found to be significantly correlated 
with the ECAS cognitive score (rs(40) = -.33, p < .05) and the ECAS behaviour domain 




The b-DAS was found to be a reliable and valid screening tool for the assessment of 
multidimensional apathy in ALS. It is psychometrically robust with good internal 
consistency and excellent test-retest reliability. When compared to the original 
informant/carer-rated DAS, this brief screening tool shows excellent content validity, 
through very strong correlations between the two measures. As the original 
informant/carer-rated DAS is composed of 24 items, the b-DAS contains the most 
psychometrically robust items (Radakovic et al., In Press) which may account for 
variability in association between the two measures. Furthermore, the b-DAS relates 
well (excellent concurrent validity) to other measures of abnormal behaviour (i.e. 
Apathy/Inertia and Loss of sympathy/empathy) as assessed by the ECAS semi-
structured behaviour interview. The b-DAS was observed to not be significantly related 
to depression, anxiety and emotional lability (excellent discriminant validity). Of note, 
while the study demonstrated characteristic Initiation apathy (34.0%) in this ALS 
patient group, there was still variability of apathy subtype impairments with Executive 
apathy (24.5%) and Emotional apathy (17.3%). This variability may increase the 
generalisability of this validation study to other neurodegenerative diseases in which 
there are different apathy profiles.  
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In terms of concurrent validity, those with apathy/inertia based on the semi-structured 
interview scored higher on all subtypes, showing effective measurement of this complex 
syndrome by the b-DAS. Further, Emotional apathy on b-DAS was also found to relate to 
loss of sympathy/empathy in the semi-structured interview, providing further validity 
to this subtype and indicative of the potential overlap between these constructs. 
Emotional apathy is defined as indifference or emotional neutrality (Radakovic & 
Abrahams, 2018), which may impact or drive responsiveness to others needs and 
feelings, and previous research has shown association with emotional recognition 
deficits and Emotional apathy (Radakovic et al., 2017). Together this may manifest as 
loss of sympathy or empathy towards family member and/or caregivers.  
 
Further, b-DAS awareness impairments were found to be associated with lower 
cognitive functioning, as well as more behavioural change. This relationship supports 
previous assertions that awareness, insight and cognitive functioning may be closely 
linked to neurodegenerative disease (Rosen, 2011). In ALS with frontotemporal 
dementia apathy, other behavioural changes and lack of insight (termed anosognosia) 
are commonly observed (Strong et al., 2017). This suggests that anosognosia for apathy 
subtypes symptoms is important to assess in such neurodegenerative diseases where 
dementia might be prominent, as made possible by the b-DAS awareness impairment 
assessment. 
 
In conclusion, the b-DAS is valid and reliable for quickly assessing symptoms of 
dimensions of apathy and the patient’s awareness of these symptoms. Furthermore, it 
can be applied within clinical and research contexts for apathy subtype profiling in 
different neurodegenerative diseases, to better understand the impact this syndrome 
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has on treatment, wellbeing and burden for people with neurological or 
neurodegenerative conditions and their families. The b-DAS will allow for objective 
assessment, and identification of deficits, in terms of real-world clinical impact to be 
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